Episodes 61-75 of 259
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
MinuteCE®Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
MinuteCE®Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
MinuteCE®Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
MinuteCE®Recent Advances in ADT: New Insights in Advanced Prostate Cancer Treatment
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Emerging targeted therapy combination strategies in genitourinary malignancies
MinuteCE®Emerging targeted therapy combination strategies in genitourinary malignancies
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Emerging immunotherapy combination strategies in genitourinary malignancies
MinuteCE®Emerging immunotherapy combination strategies in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
MinuteCE®Managing Adverse Effects of Oral vs Injectable ADT in Advanced Prostate Cancer
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
MinuteCE®First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
